Kornimate/medical-research-clean huggingface dataset:
asprosin level in individuals with periodontal disease

Conditions: Periodontitis; Periodontal Health; Gingivitis

Summary: the aim of this study was to investigate the levels of asprosin hormone and tumour necrosis factor alpha (tnf-α) in gingival crevicular fluids and to compare its level with those in saliva and serum in patients with gingivitis and periodontitis.

this study is investigating the level of asprosin hormone in gingival crevicular fluid of patients with periodontal diseases such as gingivitis and periodontitis, and observing the healthy patient in terms of the hormone levels, as well. 75 volunteer patients aged 18-45 years old were included in this study. these patients were divided equally to three groups: group i; periodontal health, group ii; gingivitis, group iii; periodontitis.the body fluids including serum, saliva and gingival crevicular fluid were collected from this participants according to the proper protocol and their storage was provided under certain conditions. elisa tests for asprosin and tumour necrosis factor alpha were made in laboratory. also, clinical measurements such as plaque index, bleeding on probing, probing pocket depth were recorded at first visit day of the participants. the data were analysed according to the different periodontal conditions, and correlated with asprosin hormone and tumour necrosis factor alpha level in gingival crevicular fluid, serum and saliva.

Eligibility criteria:
exclusion criteria: * those with any systemic disease * individuals who take medication regularly * pregnant or lactating women * individuals with menopause and anthropause * those who have undergone any periodontal treatment in the last six months * smokers

Keywords: gingival crevicular fluid asprosin hormone periodontal diseases tumour necrosis factor alpha
antisense oligonucleotide treatment for pcarp disease due to mutation in flvcr1

Conditions: Posterior Column Ataxia with Retinitis Pigmentosa

Summary: the goal of this clinical trial is to evaluate a specific antisense oligonucleotide medication in one patient with posterior column ataxia with retinitis pigmentosa. the main question it aims to answer is: what is the safety and tolerability of this medication in a single participant.


Eligibility criteria:
inclusion criteria: * informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s). * genetically confirmed flvcr1-related disease. * ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records. exclusion criteria: * allergy to any of the aso components * participant has any condition that in the opinion of the site investigator, would ultimately prevent the completion of study procedures.
a study to compare daratumumab, bortezomib, and dexamethasone (dvd) vs bortezomib and dexamethasone (vd) in chinese participants with relapsed or refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: the primary purpose of this study is to compare the efficacy of daratumumab when combined with velcade (bortezomib) and dexamethasone (dvd) to that of velcade and dexamethasone (vd), in terms of progression free survival (pfs) in chinese participants with relapsed or refractory multiple myeloma (mm).


Eligibility criteria:
inclusion criteria: * documented multiple myeloma (mm) as defined by the criteria: monoclonal plasma cells in the bone marrow greater than or equal to (\>=) 10 percent (%) at some point in the participant's disease course or presence of a biopsy-proven plasmacytoma * received at least 1 prior line of therapy for mm * documented evidence of progressive disease (pd) based on investigator's determination of response as defined by the international myeloma working group (imwg) criteria on or after their last regimen * achieved a response (partial response \[pr\] or better based on investigator's determination of response by the imwg criteria) to at least 1 prior regimen * eastern cooperative oncology group (ecog) performance status score of 0, 1, or 2 exclusion criteria: * received daratumumab or other anti-cd38 therapies * refractory to velcade, or another proteasome inhibitor (pi), like ixazomib and carfilzomib (ie, participant had progression of disease while receiving velcade therapy or within 60 days of ending velcade therapy, or another pi, like ixazomib and carfilzomib, etc) * intolerant to velcade (that is \[ie\], discontinued due to any adverse event while on velcade treatment) * planning to undergo a stem cell transplant prior to progression of disease on this study, that is ie, these participants should not be enrolled in order to reduce disease burden prior to transplant * history of malignancy (other than mm) within 3 years before the date of randomization
clinical trial comparing standard care versus prehabilitation in patients undergoing cancer surgery

Conditions: Cancer of Colon; Cancer of Rectum; Liver Metastases

Summary: to determine whether exercise and nutrition prehabilitation improves patient outcomes after cancer surgery

preliminary qualitative and quantitative studies suggest that there are benefits (reduced length of stay, improved cardiorespiratory function, reduced postoperative complications and improved quality of life) when prehabilitation is used with the context of cancer care. in 2017 macmillian cancer support developed a strategic 'evidence and insight' review on prehabilitation. the outcome of this was to incorporate prehabilitation into routine cancer care and to develop principles and guidance for prehabilitation. this study aims to support this vision and answer some of the questions on the patients who are most likely to benefit from prehabilitation and to quantify some of these benefits by investigating the molecular processes that influence clinical changes this study primarily seeks to assess the cardiovascular and biological impact of prehabilitation (exercise, nutrition) on patients undergoing hepatobiliary and colorectal cancer surgery. the investigators aim to assess whether there is an improvement in various cardiopulmonary exercise testing (cpet) variables such as maximum oxygen consumption and anaerobic threshold. the investigators also aim to study the inflammatory cytokines associated with cancer and how these markers respond to exercise. these inflammatory markers are thought to play a role in influencing some clinical outcomes such as wound infection and recovery. the study will also assess secondary outcomes including hospital stay, post operative complications and quality of life. the investigators aim to better understand the biological relationship between anti-inflammatory cytokine levels and the previously mentioned outcomes by measuring and analysing these mediators and performing selected muscle biopsies.

Eligibility criteria:
inclusion criteria: * aged 18-85 * sex: male/female * radiological/tissue cancer diagnosis * curative cancer of the colon, rectum, colorectal liver metastases (crlm) of 2 or more segments * elective surgery (planned a minimum of 3 weeks from the date of first clinic meeting) * access to digital technology(mobile phone, tablet or laptop, home computer) to participate in supervised home exercise exclusion criteria: exclusion * palliative disease * haematological malignancy * pregnancy * emergency surgery * physically unable to undergo cpet * part of any other trial with similar interventions unless previously agreed on with all cis * synchronous disease (operation on hpb \& colorectal cancers at the same operation) * no access to digital technology(smart phone, tablet, laptop or home computer)

Keywords: prehabilitation surgery cardiopulmonary exercise testing cytokines
kinetics of circulating tumor dna in lymphoma treated by immuno-chemotherapy

Conditions: Diffuse Large B Cell Lymphoma

Summary: the purpose of this study is to determine the kinetics of circulating tumor dna (ctdna) in the hours following initial administration of immuno-chemotherapy to patients with diffuse large b cell lymphoma (dlbcl). modelizing the short-term kinetics of ctdna would help to determine the optimal time-point for ctdna follow-up. the investigators hypothesize that the greater ctdna release at this time-point compared to baseline might lead lead to the detection of novel variants compared to baseline.

ctdna in diffuse large b cell lymphoma (dlbcl) has become an essential dynamic biomarker. due to its short half-life, ctdna is a real-time reflection of tumoral evolution and is a non-invasive biomarker that can be used for patient evaluation and follow-up. the quantity of ctdna before treatment is correlated with tumoral mass, international prognostic index (ipi) and prognosis. the principal mechanism of ctdna release is tumor cell apoptosis and it is well established that tumor cell apoptosis is observed in the hours following immuno-chemotherapy. however, the kinetics of ctdna concentration in the hours following immuno-chemotherapy administration is unknown. modelizing the kinetics of ctdna during this early timeframe could help to better predict chemo-sensitivity and better reflect genetic heterogeneity of the tumor, through release of a larger quantity of ctdna compared to baseline.

Eligibility criteria:
inclusion criteria: * 18 years or older * diffuse large b cell lymphoma * tep-tdm at diagnosis * inform consent form signed * performance status 0 or 1 * hospitalized on clinician decision for first cycle of r-chop or r-minichop exclusion criteria: * histology other than diffuse large b cell * patient under guardianship or curatorship * incapacity to understand the study or conform to the constraints of the study (language barrier, psychological barrier, geographic barrier...)

Keywords: diffuse large b celle lymphoma circulating tumor dna
efficacy and safety study of varying doses of lanreotide autogel in patients with acromegaly

Conditions: Acromegaly

Summary: the purpose of this study is to compare the effectiveness of lanreotide autogel to placebo after a single injection. effectiveness and safety were then also assessed following four fixed-dose injections and after one year of treatment given at titrated doses.


Eligibility criteria:
inclusion criteria: * documentation of a diagnosis of active acromegaly based on either of the following definitions: 1. the patient has never received somatostatin analog nor dopaminergic agonist or had previously received this medication but had stopped more than 3 months before visit 1 and had a mean growth hormone (gh)level \>5ng/ml at visit 1; or 2. the patient was receiving treatment with a somatostatin analog (other than lanreotide autogel) or a dopaminergic agonist at visit 1, had a mean gh \>3ng/ml at visit 2 (or visit 2a) and had at least a 100% increase in mean gh levels between visit 1 and visit 2 (or visit 2a) exclusion criteria: * receipt of radiotherapy for acromegaly within 3 years * pituitary surgery within 3 months prior to visit 1 * prior receipt of lanreotide autogel or gh antagonist * anticipated need for pituitary surgery (adenomectomy) or radiotherapy during the study period * known hypersensitivity to any of the test materials or related compounds * clinically significant renal or hepatic abnormalities
sentinel node biopsy in breast cancer: omission of axillary clearance after macrometastases. a randomized trial.

Conditions: Breast Cancer

Summary: since the introduction of sentinel node biopsy in breast cancer, it has become clear that its use is reliable and reproducible. today, it is clinical routine to not remove further lymph nodes from the axilla (arm pit) in case the sentinel node (which is the first lymph node/s reached by lymphatic flow from the breast) is free of tumor deposits. it is also routine to leave remaining lymph nodes behind in case the sentinel node contains a minimal cluster of tumor cells, called isolated tumor cells (formerly submicrometastasis). even in slightly larger tumor deposits, so called micrometastasis (up to 2 mm in size), it has been shown that a completion axillary clearance (removal of further lymph nodes from the arm pit) does not contribute to a better survival. data from a randomized study indicate that it seems safe to omit axillary clearance even if the sentinel node biopsy shows up to 2 nodes with tumor deposits over 2 mm in size (macrometastasis). these studies have changed clinical practice in many countries, however, it is still debated whether it is safe to omit axillary clearance in the case of sentinel node macrometastasis due to under-recruitment in the aforementioned study. the rationale for omitting extensive axillary surgery is the avoidance of postoperative morbidity such as arm lymphedema, loss of sensation, pain and swelling. the hypothesis is that refraining from axillary clearance in breast cancer patients with 1-2 sentinel nodes with macrometastasis will not worsen breast cancer-specific survival by more than a maximum of 2.5% after 5 years. this study is a prospective international randomized trial including 3500 patients. breast cancer patients without signs of axillary nodal involvement will be eligible for sentinel node biopsy. those who are found to have up to two sentinel node containing macrometastasis will be informed about this trial those wishing to participate will be randomized to either undergo further axillary surgery (clearance) or not. outcome measures are breast cancer-specific survival, disease-free survival, axillary recurrence rate and overall survival.

details can be found on www.senomac.se

Eligibility criteria:
inclusion criteria: * patients with invasive breast cancer (t1-t3) * n0 on palpation * preoperative ultrasound performed * pathology report shows macrometastasis in 1-2 sentinel lymph nodes * patients undergo breast-conserving therapy or mastectomy * the patient must have provided oral and written consent * age ≥ 18 years exclusion criteria: * metastases outside of the ipsilateral axilla * prior history of invasive breast cancer * pregnancy * bilateral breast cancer if one side meets exclusion criteria * medical contraindication for radiotherapy or systemic treatment * inability to absorb or understand the meaning of the study information; for example, through disability, inadequate language skills or dementia.

Keywords: sentinel node biopsy, lymph node metastasis, survival
impact of the menstrual cycle in reproductive aged women with type 1 diabetes using a closed loop system (diabetexx/1).

Conditions: Type 1 Diabetes

Summary: the aim of this observational study is to assess the effectiveness of automatic insulin infusion in responding to changes in insulin sensitivity throughout various phases of the menstrual cycle in a cohort of reproductive-aged women with type 1 diabetes, using an advanced closed-loop system. by gaining insights into both the limitations and effectiveness of this adaptation, we aim to inform the enhancement of control algorithms and learning strategies within closed-loop systems. this research is especially vital for addressing the distinct challenges that women commonly encounter in maintaining glycemic control.


Eligibility criteria:
inclusion criteria: * diagnostic criteria for dm1 according to ada * women and men treated with the medtronic© minimedtm 780g advanced closed loop system. * women presenting spontaneous regular menstrual cycles with a duration of 24 to 35 days, during the last year. * men under 50 years old. * acceptance of participation in the study and signing of the informed consent exclusion criteria: * gestation * use of hormonal contraceptives (including intrauterine devices) * institutionalization, serious or terminal illness or renal replacement therapy. * refusal to participate in the study or to sign the informed consent

Keywords: type 1 diabetes, close loop system, women
chinese adolescent registry for diabetes (card) study

Conditions: Chinese Adolescents With Diabetes

Summary: the card study is a observational study which includes chinese adolescents with diabetes aged 18-30. the study aims to explore the status of disease treatment, self-management, the relationship between disease treatment and disease outcome in chinese adolescents with diabetes.


Eligibility criteria:
inclusion criteria: * diagnosed diabetes * aged 14-30 * signed the informed consent exclusion criteria: * taking part in other drug research * gestational diabetes * diagnosed with tumor or cardiovascular disease
ultrasonic versus monopolar energy-based surgical device in colpotomy

Conditions: Gynecologic Diseases

Summary: the aim of this randomized trial was to compare the degree of surgical smoke obstructing vision and thermal damage caused by two different esds (ultrasonic versus monopolar esd) in colpotomy during total laparoscopic hysterectomy.

according to previous studies performed in porcine and bovine tissues, ultrasonic energy based surgical devices (esds) created less surgical smoke, involved less visual obstruction, and produced less lateral thermal damage than monopolar esds. however, there was no study comparing ultrasonic esd and monopolar esd in laparoscopic colpotomy in terms of surgical smoke and lateral thermal damage. therefore, the aim of this randomized trial was to compare the degree of surgical smoke obstructing vision and thermal damage caused by two different esds (ultrasonic versus monopolar esd) in colpotomy during total laparoscopic hysterectomy.

Eligibility criteria:
inclusion criteria: * women with gynecologic diseases, such as uterine myoma, adenomyosis, and ovarian tumor; * women who were planning to undergo tlh; * women between 19 and 75 years of age. exclusion criteria: * women with any suggestion of malignant cervical or vaginal pathologies * women with uncontrolled medical comorbidities or psychiatric illness, which could affect follow-up and/or compliance * women who refused to participate or give consent to the procedures.
golden walk as measure of gait rehabilitation in parkinson's disease

Conditions: Rehabilitation; Parkinson Disease; Locomotion Disorder, Neurologic; Rhythm; Abnormal

Summary: gait is specifically impaired in parkinson's disease (pd). external auditory cue based on a binary rhythm tested in pd patients disappear when the stimulus is removed. golden ratio (gr)is intrinsic in the human gait, but in pd patients this gr has been found impaired. aim of the study is the administration of an auditory external cue based on a personalized golden ratio-rhythm which could potentially assist people with pd to cope with the difficulties that they experience while walking, thus increasing their mobility and autonomy.

gait is specifically impaired in parkinson's disease (pd). external auditory cue based on a binary rhythm has been successfully used in people with pd to improve their gait quality, but the beneficial effects disappear when the stimulus is removed. recent evidences have shown that, in healthy subjects, the structure of walking relies on a number, called golden ratio (gr), based on a perfect proportion between different gait phases. while gr is known to be impaired in people with pd, there are few evidences that a gr-based auditory stimulus could support people with pd in counteracting gait alterations. as hypothesis, an auditory external cue based on a personalized gr-rhythm could assist people with pd to cope with the difficulties that they experience while walking, thus increasing their mobility and autonomy, and that the nature of this gr-rhythm allows to maintain the beneficial effects in time. two personalized auditory rhythms (a binary rhythm and a gr-rhythm) will be alternatively administered to each participant (see diagram below). patient-specific rhythms will administered by a user-friendly ad-hoc app for smartphone. two assessments will be performed during these 24 weeks, to assess treatment efficacy. at the end of the 24th week, half of patients will continue with the gr-rhythm and, in a final assessment, we will see if the effect lasts over time.

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic pd, as proposed by the brain bank criteria for pd, since at least 5 years * suffered from a rigid akinetic form of bilateral parkinson's disease (hoehn and yahr: 2-3), according to current criteria * to be on stable treatment regimen for at least the 3 months before the recruitment * mini mental state examination score \>24 * do not vary the pharmacological treatment during the entire duration of the study * be tested in "on" medication state exclusion criteria: * inability to stand or walk without aids or supports * factors affecting gait such as hip replacement, musculoskeletal disorders, uncorrected vision or vestibular problems; * inability to follow instructions; * severe dysautonomia with marked hypotension, major depression, dementia, pregnancy, or cardiac pacemaker

Keywords: golden rhythm auditory cue parkinson's disease smartphone app gait analysis
the efficacy of urine biomarker in patient with interstitial cystitis/painful bladder syndrome (pilot study)

Conditions: Chronic Interstitial Cystitis

Summary: this study is to evaluate the efficacy of urine biomarker in patients with interstitial cystitis/painful bladder syndrome


Eligibility criteria:
inclusion criteria: 1. must have experienced bladder pain, urinary urgency and frequency for at least 6 months prior to entry into the study 2. pain vas \>4 3. puf score \>13 4. icq score \>12 4) cystoscopic record within 2years exclusion criteria: 1. patients who are pregnancy or, childbearing age without no contraception 2. patient with microscopic hematuria, if not excluded that no evidence of neoplastic tumor examination 3. patients with urine culture showing evidence of urinary tract infection 1month prior to the study 4. accompanied medical problem below * tuberculosis in urinary system * bladder cancer, urethral cancer, prostate cancer * recurrent cystitis * anatomical disorder 5. patients had prior surgery (bladder augmentation, cystectomy) 6. patients with neurologic disorder 7. patients with indwelling catheter or intermittent self-catheterization 8. patients with psychological problem

Keywords: interstitial cystitis biomarker